Literature DB >> 3812262

The expert committee of the World Health Organization on classification of calcium antagonists: the viewpoint of the raporteur.

P M Vanhoutte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3812262     DOI： 10.1016/0002-9149(87)90169-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  9 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 2.  Calcium-channel blockers and anaesthesia.

Authors:  P G Durand; J J Lehot; P Foëx
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

Review 3.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

4.  Idiopathic arterial calcification of infancy.

Authors:  P J Van Reempts; K J Boven; S E Spitaels; A M Roodhooft; E L Vercruyssen; K J Van Acker
Journal:  Calcif Tissue Int       Date:  1991-01       Impact factor: 4.333

5.  Protection by verapamil and nifedipine against ischaemia-induced loss of [3H]-(+)-PN 200-110 binding sites in the rat heart.

Authors:  F T van Amsterdam; M S van Amsterdam-Magnoni; M Haas; N C Punt; J Zaagsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

Review 6.  Isradipine in hypertension.

Authors:  L Hansson
Journal:  Drugs       Date:  1990       Impact factor: 9.546

7.  Double-blind, randomized comparative study of the antihypertensive effect of nicardipine slow-release and nifedipine slow-release in hypertensive patients with coronary heart disease.

Authors:  F K Maetzel; W E Teufel; A Griebel; M H Glocke
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 8.  Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.

Authors:  T F Lüscher; Z Yang
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 9.  Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.